

ENDOCYTE INC
Form 8-K
May 01, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

April 27, 2012

Endocyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-35050

35-1969-140

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

3000 Kent Avenue, Suite A1-100, West
Lafayette, Indiana

47906

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

765-463-7175

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 7.01 Regulation FD Disclosure.

Endocyte, Inc., announced today that the U.S. Department of Justice and Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") with respect to the planned exclusive worldwide agreement between Endocyte and Merck to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145), as announced on April 16, 2012. Accordingly, the requirement under the collaboration agreement for the expiration or termination of any waiting period under the HSR Act has been satisfied.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

May 1, 2012

Endocyte, Inc.

By: */s/ Michael A. Sherman*

*Name: Michael A. Sherman
Title: Chief Financial Officer*